218 related articles for article (PubMed ID: 26536316)
1. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals.
Marcus JL; Neugebauer RS; Leyden WA; Chao CR; Xu L; Quesenberry CP; Klein DB; Towner WJ; Horberg MA; Silverberg MJ
J Acquir Immune Defic Syndr; 2016 Apr; 71(4):413-9. PubMed ID: 26536316
[TBL] [Abstract][Full Text] [Related]
2. Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.
Young J; Xiao Y; Moodie EE; Abrahamowicz M; Klein MB; Bernasconi E; Schmid P; Calmy A; Cavassini M; Cusini A; Weber R; Bucher HC;
J Acquir Immune Defic Syndr; 2015 Aug; 69(4):413-21. PubMed ID: 25932884
[TBL] [Abstract][Full Text] [Related]
3. Hypertension Risk with Abacavir Use among HIV-Infected Individuals: A Nationwide Cohort Study.
Kim J; Bang JH; Shin JY; Yang BR; Lee J; Park BJ
Yonsei Med J; 2018 Dec; 59(10):1245-1252. PubMed ID: 30450860
[TBL] [Abstract][Full Text] [Related]
4. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
Bedimo RJ; Westfall AO; Drechsler H; Vidiella G; Tebas P
Clin Infect Dis; 2011 Jul; 53(1):84-91. PubMed ID: 21653308
[TBL] [Abstract][Full Text] [Related]
5. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies.
Dorjee K; Choden T; Baxi SM; Steinmaus C; Reingold AL
Int J Antimicrob Agents; 2018 Nov; 52(5):541-553. PubMed ID: 30040992
[TBL] [Abstract][Full Text] [Related]
6. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.
Ribaudo HJ; Benson CA; Zheng Y; Koletar SL; Collier AC; Lok JJ; Smurzynski M; Bosch RJ; Bastow B; Schouten JT;
Clin Infect Dis; 2011 Apr; 52(7):929-40. PubMed ID: 21427402
[TBL] [Abstract][Full Text] [Related]
7. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.
;
AIDS; 2008 Sep; 22(14):F17-24. PubMed ID: 18753925
[TBL] [Abstract][Full Text] [Related]
8. Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study.
Lake JE; Seang S; Kelesidis T; Liao DH; Hodis HN; Stein JH; Currier JS
HIV Clin Trials; 2015 Oct; 16(5):197-206. PubMed ID: 26360501
[TBL] [Abstract][Full Text] [Related]
9. Abacavir and increased risk of myocardial infarction.
Post FA; Campbell LJ
Lancet; 2008 Sep; 372(9641):803; author reply 804-5. PubMed ID: 18774412
[No Abstract] [Full Text] [Related]
10. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.
Choi AI; Vittinghoff E; Deeks SG; Weekley CC; Li Y; Shlipak MG
AIDS; 2011 Jun; 25(10):1289-98. PubMed ID: 21516027
[TBL] [Abstract][Full Text] [Related]
11. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
Obel N; Farkas DK; Kronborg G; Larsen CS; Pedersen G; Riis A; Pedersen C; Gerstoft J; Sørensen HT
HIV Med; 2010 Feb; 11(2):130-6. PubMed ID: 19682101
[TBL] [Abstract][Full Text] [Related]
12. Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus.
Schafer JJ; Short WR; Squires KE
Pharmacotherapy; 2010 Oct; 30(10):1072-83. PubMed ID: 20874044
[TBL] [Abstract][Full Text] [Related]
13. Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study.
Dorjee K; Baxi SM; Reingold AL; Hubbard A
BMC Infect Dis; 2017 Oct; 17(1):708. PubMed ID: 29078761
[TBL] [Abstract][Full Text] [Related]
14. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
Post FA; Moyle GJ; Stellbrink HJ; Domingo P; Podzamczer D; Fisher M; Norden AG; Cavassini M; Rieger A; Khuong-Josses MA; Branco T; Pearce HC; Givens N; Vavro C; Lim ML
J Acquir Immune Defic Syndr; 2010 Sep; 55(1):49-57. PubMed ID: 20431394
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort.
Berenguer J; Pérez-Elías MJ; Bellón JM; Knobel H; Rivas-González P; Gatell JM; Miguélez M; Hernández-Quero J; Flores J; Soriano V; Santos I; Podzamczer D; Sala M; Camba M; Resino S;
J Acquir Immune Defic Syndr; 2006 Feb; 41(2):154-9. PubMed ID: 16394846
[TBL] [Abstract][Full Text] [Related]
17. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects.
King D; Tomkins S; Waters A; Easterbrook PJ; Thurmond LM; Thorborn DE; Raffi F; Kemeny DM; Vyakarnam A
J Allergy Clin Immunol; 2005 May; 115(5):1081-7. PubMed ID: 15867870
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012.
Galindo J; Amariles P; Mueses-Marín HF; Hincapié JA; González-Avendaño S; Galindo-Orrego X
BMC Infect Dis; 2016 Oct; 16(1):532. PubMed ID: 27716093
[TBL] [Abstract][Full Text] [Related]
19. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
[TBL] [Abstract][Full Text] [Related]
20. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
